This study aimed to evaluate the clinical efficacy and safety of vitamin D for preventing influenza A in 400 infants in a multicenter, randomized, open, controlled clinical trial.
The infants were randomized into low-dose and high-dose vitamin D groups, and serum calcium, inorganic phosphorus and 25-hydroxyvitamin D levels were detected thrice in 4 months. Infants infected with influenza A were monitored for symptoms including fever, cough, and wheezing. Pathogen levels and safety of vitamin D treatment were also evaluated.
Of 121 cases in total, 78 and 43 cases of influenza A infection occurred in the low-dose and high-dose vitamin D groups, respectively. There was a significant difference between the groups (χ2 = 14.6324, P = 0.0001). Among the cases of influenza infection, the median durations for fever, cough, and wheezing were shorter in the high-dose vitamin D group than in the low-dose vitamin D group. The viral loads showed a downward trend in both groups, and were significantly different between the groups at the second and third detections. Additionally, the incidences of adverse events and severe adverse events were very low and not significantly different between the two groups.
High-dose vitamin D (1200 IU) is suitable for the prevention of seasonal influenza as evidenced by rapid relief from symptoms, rapid decrease in viral loads, and disease recovery. In addition, high-dose vitamin D is probably safe for infants.
This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
1 Department Of Pediatrics, The First People's Hospital Of Yongkang, China
2Department Of Pediatrics, The Second Affiliated Hospital And Yuying Children’s Hospital Of Wenzhou Medical University, Wenzhou, China
3Department Of Pediatrics, Jinhua People’s Hospital, Jinhua, China
Acknowledgments: This study was supported by Wenzhou science and technology project, China (No. Y20140055).
Ethical approval: The present study was approved by The First People's Hospital of Yongkang Institutional Ethics Committee (approval number: 1-2015-11). All procedures involving human participants were performed in accordance with the 1964 Helsinki declaration and its later amendments, or comparable ethical standards.
Author Contributions: H.L.L. and J.Z. conceived and designed the experiments; H.L.L., L.T.H., J.Z., J.D., Y.C.W., and Y.M.S. performed the experiments; L.T.H., H.L.L., Y.C.W., and J.D. analyzed the data; J.Z. and L.T.H. contributed reagents/materials/analysis tools; and J.Z. wrote the paper.
Conflicts of Interest: The authors declare no conflicts of interest.
Corresponding Author: Hailong Lin, Department Of Pediatrics, The Second Affiliated Hospital And Yuying Children’s Hospital Of Wenzhou Medical University, 109th Xueyuanxi Road, Wenzhou, Zhejiang Province, China. Tel: +860577-88002126. E-Mail: 203004@Wzhealth.Com